Monoclonal antibodies directed against SARS-CoV-2: synthetic neutralizing antibodies, the REGN-COV2 antibody cocktail, CEBM

A monoclonal antibody “cocktail”, REGN-COV2, reduced mortality in Ebola virus infection from 51% to 34%, and the current carefully chosen pair of monoclonal antibodies against SARS-CoV-2 reduced viral replication and lung damage in experimental animals. Only randomized controlled trials in humans with COVID-19 will s how whether REGN-COV2 has clinically important benefits, with a favourable benefit to harm balance. Use outside clinical trials is currently generally unwarranted.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news